Physician profile

Neil Kaplowitz

Los Angeles, CA

NPI 1912197690

$96,212.50

in general payments reported to CMS, 2019-2025

8 companies · $2,400 in 2025

The $2,400 reported for 2025 was more than what 95% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$46,350.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Uk Limited $46,350.00 2023-2025
Pfizer INC. $22,510.00 2019-2020
Boehringer Ingelheim International Gmbh $15,042.50 2020-2021
Mitsubishi Tanabe Pharma Development America, INC. $4,060.00 2021
Grifols, S.A. $3,500.00 2021
Alkermes, INC. $3,500.00 2021
Corcept Therapeutics $1,250.00 2020

1 company reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Neil Kaplowitz

$96,212.50

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Uk Limited
Context
The $2,400 reported for 2025 was more than what 95% of providers received nationally.

https://glasscript.com/doctor/313483/neil-kaplowitz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.